Analyst Targets

• Bank of America / BofA Securities: Buy, $80 price target
• Barclays: Buy, $80 price target
• Bernstein: Buy, $79 price target
• Cantor Fitzgerald: Buy, $75 price target
• Raymond James: $75 price target
• Consensus (21 analysts): Moderate Buy, average target ~$71.78

The Setup

Centene reports Q3 2026 results before the market opens Tuesday, October 27. Analysts project earnings of roughly $0.10 per share on revenue of about $47.1 billion. The quarter lands at an inflection point: ACA open enrollment for 2027 runs November 1 through January 15 on HealthCare.gov in most states, with insurers having proposed a median premium increase of about 15% for 2027, according to KFF.

That enrollment season is the context that gives Tuesday’s numbers weight beyond a single quarter.

Company Profile

Centene is a Fortune 500 healthcare enterprise that takes a local approach to deliver fully integrated services to government-sponsored and commercial programs, focusing on under-insured individuals, covering more than 1 in 15 Americans across Medicaid, Medicare, and the Health Insurance Marketplace. It currently offers Marketplace plans in 29 states.

Centene is the largest Marketplace carrier. That distinction is both a competitive advantage and the source of its singular risk heading into 2027 enrollment.

The Numbers to Watch

The Zacks consensus estimate for Q3 stands at 7 cents per share on revenues of $47.06 billion. On an adjusted diluted basis, that would be down 86% from $0.50 per share in the year-ago quarter. The EPS figure alone tells little of the story.

What the market will actually price is the health benefits ratio. Centene’s full-year 2026 HBR guidance is 88.3%. The Q2 2026 consolidated HBR came in at 89.6%, down from 93.0% in the year-ago period. Q3 needs to confirm the trajectory is holding, not reversing. For context, Centene has beaten earnings estimates in each of the last four quarters, with an average surprise of 151.3%.

Why the HBR Is the Only Line That Matters

Centene is the managed-care name most exposed to exchange risk pools, and those pools are deteriorating in ways that matter for medical cost ratios. The company’s exchange membership fell from 5.6 million at the end of 2025 to 3.6 million by Q1, with further declines expected through 2026.

ACA Marketplace insurers have proposed a median premium increase of about 15% for 2027, the second consecutive year of double-digit hikes. Higher premiums can accelerate the adverse selection cycle: healthier members drop coverage, sicker ones stay, and HBR creeps up. UnitedHealthcare has said it plans to scale back its ACA exchange footprint for 2027, including exiting some states. Centene has far less room to shrink without ceding its leadership position; it remains the sector’s most direct large-cap expression of exchange risk.

Macro Context

The sector got a lift this week when RBC Capital raised its UnitedHealth price target to $498 from $478 and kept its Outperform rating, sending UNH up 3.5%. Humana gained 3.4%, Centene 2.8%, and Elevance Health 2.0%. The raise followed UnitedHealth’s Q3 report on October 13, where adjusted EPS of $4.69 beat consensus by 57 cents and the medical care ratio of 88.4% came in below the 89.9% the Street expected.

The managed-care sector’s fortunes are not moving in lockstep. Humana’s Medicare Advantage star-rating recovery unlocks a separate earnings catalyst that insulates it from exchange-pool deterioration.

UNH’s beat raises the question of whether Centene can deliver the same. The businesses are different. UNH has Medicare Advantage diversification. Centene is disproportionately tied to exchange members who are, structurally, getting sicker.

The gap between UNH and Centene is not just business mix — it is how the market rewards a medical cost ratio that comes in below expectations. UnitedHealth’s managed care rally showed how quickly a cooling cost ratio can reprice the entire sector.

Bull / Base / Bear

Bull: HBR comes in around the 88.3% full-year guide. Management reaffirms full-year adjusted EPS above $4.80 and provides constructive commentary on early 2027 enrollment pricing. Stock tests the $75 to $80 analyst target range.

Base: HBR comes in between 88.5% and 89.5%, guidance holds, but the 2027 risk-pool outlook stays murky. Stock digests in the $63 to $69 range near current levels.

Bear: HBR surprises above 90%, the Q2 improvement proves temporary, and management cuts or qualifies the EPS guide. Medicaid membership is already expected to decline 8% to 9% by year-end; a medical cost miss on top of enrollment erosion would reset estimates materially lower.

Technical Overlay

CNC has recovered sharply from its 52-week low of $31.63, trading near $63 to $69 ahead of the print. The 52-week range runs $31.63 to $72.50. The $70 to $71 zone represents an overhead level a clean HBR beat would need to clear and hold.

Bottom Line

This is not a revenue quarter. Analysts already expect an earnings decline year over year. The market will look past both. What it is pricing is whether Centene’s medical cost trajectory remains intact as the exchange risk pool it runs heads into its most disruptive enrollment season in years. The HBR either confirms a durable margin recovery or reopens a debate that the stock spent most of 2026 trying to close.